Achieve Life Sciences (ACHV) Cash from Financing Activities (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Cash from Financing Activities of $21000.0 in Q1 2026, down 99.66% on a QoQ basis from $6.3 million in Q4 2025.
Achieve Life Sciences (ACHV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $21000.0 for Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $21000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (changed N/A YoY) and the FY2025 annual result came in at $51.5 million, up 6.18% from the prior year.
- Cash from Financing Activities eased to $21000.0 in Q1 2026, from $6.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $56.1 million in Q1 2024 and troughed at -$8.1 million in Q3 2024.
- A 5-year average of $7.2 million and a median of $682000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Biggest YoY gain for Cash from Financing Activities was 119282.98% in 2024; the steepest drop was 101.0% in 2024.
- Tracing ACHV's Cash from Financing Activities over 5 years: stood at $17.7 million in 2022, then dropped by 14.01% to $15.2 million in 2023, then slumped by 95.52% to $682000.0 in 2024, then jumped by 818.33% to $6.3 million in 2025, then tumbled by 99.66% to $21000.0 in 2026.
- Business Quant data shows ACHV's Cash from Financing Activities at $21000.0 in Q1 2026, $6.3 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 85,464.43 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,000.00 |
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | 6.26 Mn |
| Dec 31, 2025 | 6.26 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Dec 31, 2024 | 682,000.00 |
| Dec 31, 2024 | 682,000.00 |
| Sep 30, 2024 | -8.11 Mn |
| Sep 30, 2024 | -8.11 Mn |
| Jun 30, 2024 | -153,000.00 |
| Jun 30, 2024 | -153,000.00 |
| Mar 31, 2024 | 56.11 Mn |
| Mar 31, 2024 | 56.11 Mn |
| Jun 30, 2023 | 15.23 Mn |
| Jun 30, 2023 | 15.23 Mn |
| Mar 31, 2023 | 47,000.00 |
| Mar 31, 2023 | 47,000.00 |
| Dec 31, 2022 | 17.71 Mn |
| Dec 31, 2022 | 17.71 Mn |